Publications by authors named "T M Kundig"
Article Synopsis
- * Results showed a significant reduction in the Psoriasis Area and Severity Index (PASI) after 3 and 18 months, with many patients achieving low PASI scores, indicating effective treatment.
- * Improvements in quality of life were noted, and no patients discontinued treatment due to adverse events, suggesting that tildrakizumab has a strong safety profile in a real-world setting.
Real-world data on anatomically localized psoriasis and its response to systemic therapy across different age-groups and sexes is limited. This study aimed to evaluate the severity and distribution of psoriasis over time in female and male patients receiving systemic therapies, categorized by age within the Swiss psoriasis registry (SDNTT). Patient-data was obtained over 11 years through the SDNTT.
View Article and Find Full Text PDFPredicting Psoriatic Arthritis in Psoriasis Patients - A Swiss Registry Study.
J Psoriasis Psoriatic Arthritis
April 2024
Background: Psoriatic arthritis (PsA) is a prevalent comorbidity among patients with psoriasis, heavily contributing to their burden of disease, usually diagnosed several years after the diagnosis of psoriasis.
Objectives: To investigate the predictability of psoriatic arthritis in patients with psoriasis and to identify important predictors.
Methods: Data from the Swiss Dermatology Network on Targeted Therapies (SDNTT) involving patients treated for psoriasis were utilized.
Synthetic mRNA produced by in vitro transcription (ivt mRNA) is the active pharmaceutical ingredient of approved anti-COVID-19 vaccines and of many drugs under development. Such synthetic mRNA typically contains several hundred bases of non-coding "untranslated" regions (UTRs) that are involved in the stabilization and translation of the mRNA. However, UTRs are often complex structures, which may complicate the entire production process.
View Article and Find Full Text PDFBackground: Biologics are among the most effective therapies for psoriasis. However, many patients are only introduced to them at advanced stages of the disease course.
Objectives: Our aim was to identify predictors of initiating biologic therapy in patients with psoriasis and compare patients initiating biologics early versus late in their disease course.